1.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

2.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

3.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

4.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

5.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

6.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

7.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

8.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

9.

Growth response of syndromic versus non-syndromic children born small for gestational age (SGA) to growth hormone therapy: a Belgian study.

1.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

2.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

3.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

4.

Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

1.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

2.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

3.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

4.

Novel missense mutation in the caveolin-3 gene in a Belgian family with rippling muscle disease.

1.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

2.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

3.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

1.

Neonatal screening improves sickle cell disease clinical outcome in Belgium.

2.

Neonatal screening improves sickle cell disease clinical outcome in Belgium.

3.

Neonatal screening improves sickle cell disease clinical outcome in Belgium.

1.

Organ donation in Belgium 2011: the highest donation rate ever

2.

Organ donation in Belgium 2011: the highest donation rate ever

3.

Organ donation in Belgium 2011: the highest donation rate ever

1.

Clinical characteristics and humoral immune response in healthcare workers with COVID-19 in a teaching hospital in Belgium.

2.

Clinical characteristics and humoral immune response in healthcare workers with COVID-19 in a teaching hospital in Belgium.

3.

Clinical characteristics and humoral immune response in healthcare workers with COVID-19 in a teaching hospital in Belgium.

1.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

2.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

3.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

1.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

2.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

3.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

4.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

5.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

6.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

7.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

8.

Burden of illness in patients with chronic hypoparathyroidism not adequately controlled with conventional therapy: a Belgium and the Netherlands survey.

1.

Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.

2.

Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.

3.

Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.

1.

Epidemiology of the Staphylococcus aureus CA-MRSA USA300 in Belgium.

1.

Outbreak of infection by carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-58 in Belgium.

2.

Outbreak of infection by carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-58 in Belgium.

3.

Outbreak of infection by carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-58 in Belgium.

1.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

2.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

3.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

1.

Female representation in orthopedic surgery: where do we stand in Belgium ?

2.

Female representation in orthopedic surgery: where do we stand in Belgium ?

3.

Female representation in orthopedic surgery: where do we stand in Belgium ?

1.

Do social class differentials in health and health behaviours exist in young people (15-to-24-year-olds) in Belgium ?

1.

Epidemiology of multidrug-resistant microorganisms among nursing home residents in Belgium.

1.

Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.

1.

Nationwide population-based cohort study of uterine rupture in Belgium: Results from the Belgian obstetric surveillance system

2.

Nationwide population-based cohort study of uterine rupture in Belgium: Results from the Belgian obstetric surveillance system

1.

Ten-year changes in diet quality among adolescents and young adults (Food Consumption Survey 2004 and 2014, Belgium)

1.

Seat belt use and social inequality in Belgium

1.

Evaluation of the SARS-CoV-2 positivity ratio and upper respiratory tract viral load among asymptomatic individuals screened before hospitalization or surgery in Flanders, Belgium

2.

Evaluation of the SARS-CoV-2 positivity ratio and upper respiratory tract viral load among asymptomatic individuals screened before hospitalization or surgery in Flanders, Belgium

1.

Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up

1.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

2.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

3.

Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.

1.

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.

2.

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.

1.

Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants ; Bon continuum de soins de l'infection HIV en Belgique malgré les faibless...

2.

Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants ; Bon continuum de soins de l'infection HIV en Belgique malgré les faibless...

1.

Psychometric properties of the temperament and character inventory-revised (TCI-R) in a Belgian sample.

2.

Psychometric properties of the temperament and character inventory-revised (TCI-R) in a Belgian sample.

3.

Psychometric properties of the temperament and character inventory-revised (TCI-R) in a Belgian sample.

1.

Robot-assisted surgery for women with endometrial cancer: Surgical and oncologic outcomes within a Belgium gynaecological oncology group cohort.

1.

Health literacy among asthma patients and treatment expectations: results of a Belgian survey.

2.

Health literacy among asthma patients and treatment expectations: results of a Belgian survey.

3.

Health literacy among asthma patients and treatment expectations: results of a Belgian survey.

4.

Health literacy among asthma patients and treatment expectations: results of a Belgian survey.

5.

Health literacy among asthma patients and treatment expectations: results of a Belgian survey.

6.

Health literacy among asthma patients and treatment expectations: results of a Belgian survey.

7.

Health literacy among asthma patients and treatment expectations: results of a Belgian survey.

8.

Health literacy among asthma patients and treatment expectations: results of a Belgian survey.

1.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

2.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

1.

Robot-Assisted Radical Hysterectomy in Cervical Carcinoma: The Belgian Experience.

2.

Robot-Assisted Radical Hysterectomy in Cervical Carcinoma: The Belgian Experience.

3.

Robot-Assisted Radical Hysterectomy in Cervical Carcinoma: The Belgian Experience.

1.

Human Chorionic Gonadotropin Regression Curves after Partial or Complete Molar Pregnancy in Flanders: Are They Different from Regression Curves from the Eighties?

1.

What do the needles, syringes, lancets and reagent strips of diabetic patients become in the absence of a common attitude? About 1070 questionnaires in diabetic clinics.

1.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

2.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

3.

Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience.

1.

Evidence that the Two-Way Communication Checklist identifies patient-doctor needs discordance resulting in better 6-month outcome.

1.

Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium.

1.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

2.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

3.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

1.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

2.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

3.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

4.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

5.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

6.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

7.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

8.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.

9.

Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients.